Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $426.31 | 23 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $247.23 | 13 | $0 (2024) |
| AbbVie Inc. | $40.51 | 2 | $0 (2023) |
| Lundbeck LLC | $25.43 | 2 | $0 (2018) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.08 | 1 | $0 (2024) |
| Neos Therapeutics, LP | $20.19 | 1 | $0 (2018) |
| Almatica Pharma LLC | $19.85 | 1 | $0 (2024) |
| Axsome Therapeutics, Inc. | $19.23 | 1 | $0 (2023) |
| Neurocrine Biosciences, Inc. | $18.50 | 1 | $0 (2024) |
| Allergan Inc. | $14.29 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $120.37 | 6 | Otsuka America Pharmaceutical, Inc. ($60.94) |
| 2023 | $56.93 | 3 | Otsuka America Pharmaceutical, Inc. ($19.50) |
| 2022 | $22.31 | 1 | ABBVIE INC. ($22.31) |
| 2018 | $75.98 | 5 | Lundbeck LLC ($25.43) |
| 2017 | $150.72 | 8 | Otsuka America Pharmaceutical, Inc. ($150.72) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Neuropsychiatry | ||||||
| 04/16/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: ANTI-ANXIETY | ||||||
| 03/19/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $26.30 | General |
| Category: PSYCHIATRY | ||||||
| 02/21/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: PSYCHIATRY | ||||||
| 01/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: PSYCHIATRY | ||||||
| 01/09/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: PSYCHIATRY | ||||||
| 12/01/2023 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: Psychology/Psychiatric | ||||||
| 09/07/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: PSYCHIATRY | ||||||
| 05/11/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2018 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: PSYCHIATRY | ||||||
| 11/26/2018 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $13.25 | General |
| Category: PSYCHIATRY | ||||||
| 10/24/2018 | Neos Therapeutics, LP | Cotempla XR-ODT (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: ADHD | ||||||
| 06/18/2018 | Allergan Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/19/2018 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $12.18 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2017 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2017 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $2.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/31/2017 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/09/2017 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/02/2017 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: PSYCHIATRY | ||||||
| 09/18/2017 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: PSYCHIATRY | ||||||
| 09/18/2017 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: PSYCHIATRY | ||||||
| 09/05/2017 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 39 | 80 | $20,215 | $6,909 |
| 2022 | 3 | 281 | 709 | $85,000 | $59,962 |
| 2021 | 7 | 585 | 1,925 | $217,050 | $155,795 |
| 2020 | 9 | 797 | 2,183 | $234,503 | $125,232 |
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 80 | $20,215 | $6,909 | 34.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 164 | 481 | $56,099 | $42,584 | 75.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 105 | 203 | $23,676 | $15,674 | 66.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 25 | $5,225 | $1,704 | 32.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 188 | 885 | $103,218 | $81,936 | 79.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 172 | 467 | $54,466 | $39,915 | 73.3% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2021 | 55 | 215 | $20,870 | $13,834 | 66.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 61 | 245 | $20,920 | $13,533 | 64.7% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 13 | 13 | $2,894 | $2,239 | 77.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 28 | 32 | $6,752 | $2,201 | 32.6% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 68 | 68 | $7,931 | $2,136 | 26.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 171 | 586 | $68,345 | $41,978 | 61.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 205 | 615 | $60,209 | $32,413 | 53.8% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 156 | 413 | $48,168 | $18,144 | 37.7% |
| 90836 | Psychotherapy, 45 minutes | Office | 2020 | 65 | 246 | $22,240 | $16,673 | 75.0% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 94 | 136 | $15,862 | $4,691 | 29.6% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 39 | 115 | $5,890 | $4,301 | 73.0% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 27 | 27 | $6,156 | $3,451 | 56.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 17 | 20 | $2,333 | $1,866 | 80.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 23 | 25 | $5,300 | $1,714 | 32.3% |
About Dr. Valeriy Chernov, MD
Dr. Valeriy Chernov, MD is a Psychiatry healthcare provider based in North Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144232257.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Valeriy Chernov, MD has received a total of $426.31 in payments from pharmaceutical and medical device companies, with $120.37 received in 2024. These payments were reported across 23 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($426.31).
As a Medicare-enrolled provider, Chernov has provided services to 1,702 Medicare beneficiaries, totaling 4,897 services with total Medicare billing of $347,898. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Practice Information
- Specialty Psychiatry
- Other Specialties Child & Adolescent Psychiatry, Psychiatry
- Location North Miami, FL
- Active Since 08/13/2006
- Last Updated 01/15/2024
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1144232257
Products in Payments
- REXULTI (Drug) $200.52
- ABILIFY MAINTENA (Drug) $72.14
- VRAYLAR (Drug) $40.51
- CAPLYTA (Drug) $21.08
- Cotempla XR-ODT (Drug) $20.19
- LOREEV XR (Drug) $19.85
- Auvelity (Drug) $19.23
- INGREZZA (Drug) $18.50
- VIBERZI (Drug) $14.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in North Miami
Dr. Alphonse Hayeck, M.d, M.D
Psychiatry — Payments: $590.29
Dr. Victor Vasquez, Do, DO
Psychiatry — Payments: $86.43
Vinaya Koppikar, Md, MD
Psychiatry — Payments: $25.79
Dr. Daniel Collins, Md, MD
Psychiatry — Payments: $17.13
Santiago Castaneda-Ramirez, Md, MD
Psychiatry
Nirmit Desai, Md, MD
Psychiatry